Annals of Surgical Oncology

, Volume 18, Issue 8, pp 2318–2328 | Cite as

A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma

  • Nigel B. Jamieson
  • Simon M. Denley
  • Jennifer Logue
  • Douglas J. MacKenzie
  • Alan K. Foulis
  • Euan J. Dickson
  • Clem W. Imrie
  • Ross Carter
  • Colin J. McKay
  • Donald C. McMillan
Pancreatic Tumors



Outcome prediction after resection with curative intent for pancreatic ductal adenocarcinoma remains a challenge. There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients undergoing resection for a variety of common solid tumors. Our aim was to prospectively evaluate the prognostic value of tumor- and patient-related factors including the systemic inflammatory response in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma of the head of pancreas.


The prognostic impact of tumor factors such as stage and host factors, including the systemic inflammatory response (modified Glasgow Prognostic Score [mGPS]), were evaluated in a prospective study of 135 patients who underwent elective pancreaticoduodenectomy for pancreatic ductal adenocarcinoma from January 2002 to April 2009.


In addition to the established tumor-related pathological factors (in particular margin involvement; hazard ratio [HR] 2.82, 95% confidence interval [CI] 1.65–4.84, P < 0.001), an elevated mGPS (HR 2.26, 95% CI 1.43–3.57, P < 0.001) was independently associated with lower overall survival after pancreaticoduodenectomy. Additionally, in an adjuvant therapy subgroup of 74 patients, both margin involvement and an elevated mGPS remained independently associated with reduced overall survival.


We have prospectively validated the influence of tumor-related and patient-related factors. Margin involvement and the preoperative mGPS were the most important determinants of overall survival in patients undergoing potentially curative pancreaticoduodenectomy. Furthermore, both had independent prognostic value in those patients receiving adjuvant chemotherapy. In the future, this may be considered a stratification factor for entry onto therapeutic trials.


Pancreatic Ductal Adenocarcinoma Venous Invasion Preoperative Biliary Drainage Univariate Survival Analysis Biliary Decompression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



N.B.J. undertook this work while supported by a Clinical PhD Fellowship from the Chief Scientist’s Office of the Scottish Government. The authors thank Dr. Ian Stewart for diagnostic imaging, Dr. Alex MacDonald for medical oncology management, pancreatic audit secretary Diane Stewart, and the West of Scotland Pancreatic Unit nurse specialists Elspeth Cowan, Alison Sinclair, and Linda Dewar for follow-up data.


  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Luttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191:154–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.PubMedCrossRefGoogle Scholar
  5. 5.
    van Roest MH, Gouw AS, Peeters PM, et al. Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. Ann Surg. 2008;248:97–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–210.PubMedCrossRefGoogle Scholar
  8. 8.
    Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251:1003–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–8.PubMedCrossRefGoogle Scholar
  11. 11.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Vashist YK, Loos J, Dedow J, et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. doi: 10.1245/s10434-010-1383-7.
  14. 14.
    McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Jamieson NB, Glen P, McMillan DC, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 2005;92:21–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Glen P, Jamieson NB, McMillan DC, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Monreal M, Fernandez-Llamazares J, Pinol M, et al. Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916–8.PubMedGoogle Scholar
  20. 20.
    Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Kandemir EG, Mayadagli A, Karagoz B, et al. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005;33:228–35.PubMedGoogle Scholar
  22. 22.
    Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12:1422–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758–68.PubMedCrossRefGoogle Scholar
  26. 26.
    Greene FL, Page DL, Fleming ID, et al. Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, et al, editors. AJCC cancer staging manual, 6th ed. New York: Springer; 2002. p. 157–64.Google Scholar
  27. 27.
    Royal College of Pathologists. Standards and minimum datasets for reporting cancers. minimum dataset for the histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. London: Royal College of Pathologists; 2002. Google Scholar
  28. 28.
    Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer. 2006;14:999–1011.PubMedCrossRefGoogle Scholar
  30. 30.
    Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23:6240–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109:205–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160:861–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27:2855–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651–60.PubMedCrossRefGoogle Scholar
  35. 35.
    Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93:1232–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Smith RA, Dajani K, Dodd S, et al. Preoperative resolution of jaundice following biliary stenting predicts more favourable early survival in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2008;15:3138–46.PubMedCrossRefGoogle Scholar
  37. 37.
    Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55–60.PubMedGoogle Scholar
  38. 38.
    Sewnath ME, Karsten TM, Prins MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2002;236:17–27.PubMedCrossRefGoogle Scholar
  39. 39.
    van der Gaag NA, Rauws EJA, van Eijick CHJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:130–7.Google Scholar
  40. 40.
    Sharma R, Zucknick M, London R, et al. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7:331–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Kobayashi T, Teruya M, Kishiki T, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008;144:729–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Crozier JE, McKee RF, McArdle CS, et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006;94:1833–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009;250:268–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med. 2010;88:85–92.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Nigel B. Jamieson
    • 1
  • Simon M. Denley
    • 1
  • Jennifer Logue
    • 1
  • Douglas J. MacKenzie
    • 1
  • Alan K. Foulis
    • 2
  • Euan J. Dickson
    • 3
  • Clem W. Imrie
    • 3
  • Ross Carter
    • 3
  • Colin J. McKay
    • 3
  • Donald C. McMillan
    • 1
  1. 1.Department of SurgeryGlasgow UniversityGlasgowScotland, UK
  2. 2.Department of PathologyGlasgow UniversityGlasgowScotland, UK
  3. 3.West of Scotland Pancreatic UnitGlasgow Royal Infirmary, Alexandra ParadeGlasgowScotland, UK

Personalised recommendations